Bank of New York Mellon’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Bank of New York Mellon’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,175	Closed	-$11K	–	4778
2022 Q1	$11K	Hold	2,175	–	–	﹤0.01%	4640
2021 Q4	$12K	Hold	2,175	–	–	﹤0.01%	4610
2021 Q3	$24K	Hold	2,175	–	–	﹤0.01%	4498
2021 Q2	$37K	Sell	2,175 -14,784	-87%	-$280K	﹤0.01%	4360
2021 Q1	$446K	Buy	16,959 +2,872	+20%	+$131K	﹤0.01%	3747
2020 Q4	$509K	Buy	14,087 +408	+3%	+$14.8K	﹤0.01%	3608
2020 Q3	$484K	Buy	13,679 +5,020	+58%	+$218K	﹤0.01%	3505
2020 Q2	$368K	Buy	8,659 +6,197	+252%	+$418K	﹤0.01%	3616
2020 Q1	$196K	Buy	2,462 +67	+3%	+$5.36K	﹤0.01%	3743
2019 Q4	$221K	Buy	2,395 +329	+16%	+$27.8K	﹤0.01%	3890
2019 Q3	$156K	Sell	2,066 -97	-4%	-$7.45K	﹤0.01%	3955
2019 Q2	$215K	Buy	+2,163	New	+$168K	﹤0.01%	3898
2016 Q3	–	Sell	-114	Closed	-$10K	–	4331
2016 Q2	$10K	Buy	+114	New	+$10.2K	﹤0.01%	4294
2015 Q2	–	Sell	-278	Closed	-$205K	–	4345
2015 Q1	$205K	Sell	278 -4	-1%	-$2.56K	﹤0.01%	3889
2014 Q4	$190K	Buy	+282	New	+$213K	﹤0.01%	3903

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon's EVFM Position: Q2 2022 in Review

Bank of New York Mellon sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 2,175 shares — an estimated $11K sold.

Bank of New York Mellon first reported a position in EVFM in Q4 2014 and held it in 15 quarters. The position peaked at $509K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Bank of New York Mellon reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 2,175 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $11K.
Bank of New York Mellon first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
Bank of New York Mellon's Evofem Biosciences, Inc. Common Stock position peaked at $509K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.